Switzerland · Delayed Price · Currency is CHF medmix AG Statistics
Total Valuation
medmix AG has a market cap or net worth of CHF 359.84 million. The enterprise value is 575.74 million.
| Market Cap | 359.84M |
| Enterprise Value | 575.74M |
Important Dates
The last earnings date was Thursday, July 23, 2026.
| Earnings Date | Jul 23, 2026 |
| Ex-Dividend Date | Apr 20, 2026 |
Share Statistics
medmix AG has 40.71 million shares outstanding. The number of shares has increased by 12.25% in one year.
| Current Share Class | 40.71M |
| Shares Outstanding | 40.71M |
| Shares Change (YoY) | +12.25% |
| Shares Change (QoQ) | +20.34% |
| Owned by Insiders (%) | 44.60% |
| Owned by Institutions (%) | 21.85% |
| Float | 22.55M |
Valuation Ratios
The trailing PE ratio is 3,598.43 and the forward PE ratio is 17.44.
| PE Ratio | 3,598.43 |
| Forward PE | 17.44 |
| PS Ratio | 0.82 |
| PB Ratio | 0.83 |
| P/TBV Ratio | 5.90 |
| P/FCF Ratio | 11.35 |
| P/OCF Ratio | 6.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.73, with an EV/FCF ratio of 18.16.
| EV / Earnings | 5,757.43 |
| EV / Sales | 1.32 |
| EV / EBITDA | 7.73 |
| EV / EBIT | 32.53 |
| EV / FCF | 18.16 |
Financial Position
The company has a current ratio of 1.52, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.52 |
| Quick Ratio | 1.08 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 4.29 |
| Debt / FCF | 10.08 |
| Interest Coverage | 1.28 |
Financial Efficiency
Return on equity (ROE) is 0.21% and return on invested capital (ROIC) is 2.90%.
| Return on Equity (ROE) | 0.21% |
| Return on Assets (ROA) | 1.88% |
| Return on Invested Capital (ROIC) | 2.90% |
| Return on Capital Employed (ROCE) | 2.26% |
| Weighted Average Cost of Capital (WACC) | 5.96% |
| Revenue Per Employee | 168,922 |
| Profits Per Employee | 39 |
| Employee Count | 2,587 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.44 |
Taxes
In the past 12 months, medmix AG has paid 500,000 in taxes.
| Income Tax | 500,000 |
| Effective Tax Rate | 35.71% |
Stock Price Statistics
The stock price has decreased by -27.42% in the last 52 weeks. The beta is 0.82, so medmix AG's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -27.42% |
| 50-Day Moving Average | 8.41 |
| 200-Day Moving Average | 9.46 |
| Relative Strength Index (RSI) | 65.90 |
| Average Volume (20 Days) | 140,488 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, medmix AG had revenue of CHF 437.00 million and earned 100,000 in profits.
| Revenue | 437.00M |
| Gross Profit | 160.50M |
| Operating Income | 28.90M |
| Pretax Income | 1.40M |
| Net Income | 100,000 |
| EBITDA | 74.50M |
| EBIT | 17.70M |
| Earnings Per Share (EPS) | -0.00 |
Balance Sheet
The company has 111.30 million in cash and 319.40 million in debt, with a net cash position of -208.10 million or -5.11 per share.
| Cash & Cash Equivalents | 111.30M |
| Total Debt | 319.40M |
| Net Cash | -208.10M |
| Net Cash Per Share | -5.11 |
| Equity (Book Value) | 432.80M |
| Book Value Per Share | 10.44 |
| Working Capital | 99.00M |
Cash Flow
In the last 12 months, operating cash flow was 59.30 million and capital expenditures -27.60 million, giving a free cash flow of 31.70 million.
| Operating Cash Flow | 59.30M |
| Capital Expenditures | -27.60M |
| Depreciation & Amortization | 42.70M |
| Net Borrowing | -11.20M |
| Free Cash Flow | 31.70M |
| FCF Per Share | 0.78 |
Margins
Gross margin is 36.73%, with operating and profit margins of 6.61% and 0.02%.
| Gross Margin | 36.73% |
| Operating Margin | 6.61% |
| Pretax Margin | 0.32% |
| Profit Margin | 0.02% |
| EBITDA Margin | 17.05% |
| EBIT Margin | 4.05% |
| FCF Margin | 7.25% |
Dividends & Yields
This stock pays an annual dividend of 0.10, which amounts to a dividend yield of 1.13%.
| Dividend Per Share | 0.10 |
| Dividend Yield | 1.13% |
| Dividend Growth (YoY) | -80.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 8,700.00% |
| Buyback Yield | -12.25% |
| Shareholder Yield | -11.11% |
| Earnings Yield | 0.03% |
| FCF Yield | 8.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for medmix AG is 15.80, which is 78.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 15.80 |
| Price Target Difference | 78.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 3.19% |
| EPS Growth Forecast (3Y) | -4.06% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
medmix AG has an Altman Z-Score of 1.84 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 5 |